Cargando…

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a genetically and clinically heterogeneous malignancy affecting older individuals. There are a number of current treatment options for CLL, including monoclonal antibodies, targeted drugs, chemotherapy, and different combinations of these. However, for those pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aptullahoglu, Erhan, Wallis, Jonathan P., Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379212/ https://www.ncbi.nlm.nih.gov/pubmed/37511096 http://dx.doi.org/10.3390/ijms241411335

Ejemplares similares

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
por: Ciardullo, Carmela, et al.
Publicado: (2019)

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
por: Aptullahoglu, Erhan, et al.
Publicado: (2023)

Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia
por: Barrow, Timothy M., et al.
Publicado: (2020)

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia
por: Schwaederlé, M, et al.
Publicado: (2013)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia
por: Sookaromdee, Pathum, et al.
Publicado: (2019)

p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)

SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis
por: Zhang, Zhenghao, et al.
Publicado: (2017)

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
por: Lin, Wei-Yu, et al.
Publicado: (2021)

Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients
por: Sadria, Reza, et al.
Publicado: (2022)

Investigation of MDM2 Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia
por: Darbaş, Şule, et al.
Publicado: (2019)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns
por: Tang, Alison D., et al.
Publicado: (2020)

SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia
por: Szoltysek, Katarzyna, et al.
Publicado: (2020)

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53(WT) Uterine Leiomyosarcoma
por: Chamberlain, Victoria, et al.
Publicado: (2021)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

KMT Set7/9 affects genotoxic stress response via the Mdm2 axis
por: Lezina, Larissa, et al.
Publicado: (2015)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukemia
por: Barrow, Timothy M., et al.
Publicado: (2020)

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
por: Jiang, Liren, et al.
Publicado: (2019)

Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3
por: Putowski, Maciej, et al.
Publicado: (2021)

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2017)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
por: Rimondi, Erika, et al.
Publicado: (2021)

Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
por: Pechackova, Sona, et al.
Publicado: (2016)

Genotoxicity induced by iodine-131 in human cultured lymphocytes
por: Hosseinimehr, Seyed Jalal, et al.
Publicado: (2013)

Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells
por: Mukherjee, Sanjay, et al.
Publicado: (2022)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015)

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans
por: Xia, Yi, et al.
Publicado: (2014)

A feedback circuit of miR-34a/MDM4/p53 regulates apoptosis in chronic lymphocytic leukemia cells
por: Cao, Lei, et al.
Publicado: (2020)

Mutational landscape and underlying mutational processes in chronic lymphocytic leukemia
por: Kasar, S., et al.
Publicado: (2016)

Evaluation of Possible Genotoxic Activity of Dirithromycin in Cultured Human Lymphocytes
por: Kayraldız, Ahmet, et al.
Publicado: (2015)

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
por: Wu, Chiao-En, et al.
Publicado: (2019)

Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma
por: Post, Sean M., et al.
Publicado: (2010)

Pediatric chronic myeloid leukemia with B-cell lymphoid blast crisis at presentation
por: Iyer, Prasad, et al.
Publicado: (2013)

Anatomy of Mdm2 and Mdm4 in evolution
por: Tan, Ban Xiong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c0bk2ps81ke70mbnonjuu6ne85